MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 7, 2004; DOI: 10.1124/mol.104.003913


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.003913v1
67/3/695    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakata, H.
Right arrow Articles by Kozasa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakata, H.
Right arrow Articles by Kozasa, T.


Received for publication June 15, 2004.
Revised December 4, 2004.
Accepted for publication December 6, 2004.

Functional characterization of G{alpha}o signaling through GRIN1

Hiroko Nakata 1 Tohru Kozasa 1*

1 University of Illinois at Chicago

* Address correspondence to: E-mail: tkozas{at}uic.edu

Abstract

GRIN1 (G protein-regulated inducer of neurite outgrowth 1) was initially identified as a binding protein for GTP{gamma}gS-bound G{alpha}z. GRIN1 is specifically expressed in brain and interacts selectively with activated {alpha}subunits of Gi subfamily. GRIN1 colocalizes with G{alpha}o at the growth cone of neuronal cells and promotes neurite extention in Neuro2a cells when co-expressed with constitutively active mutant G{alpha}oQ205L. These results suggest that GRIN1 functions as a downstream target for G{alpha}o. However, GRIN1 does not contain domains that are homologous to known signaling motifs. To understand the mechanisms of G{alpha}o-GRIN1 pathway, we analyzed functional domains of GRIN1 that are involved in binding with G{alpha}o or its targeting to the plasma membrane. Using pull down assays with GST-fused GRIN1 deletion mutants, G{alpha}o binding regions were localized to amino acid residues 716-746 and 797-827 of GRIN1. The G{alpha}o binding region of GRIN1 did not demonstrate GTPase accelerating activity for G{alpha}o. GRIN1 localized in the cell periphery in Neuro2a cells, and two cysteine residues at C-terminal region of GRIN1 (Cys818 and Cys819) were shown to be critical for its membrane targeting. Co-expression of GRIN1 with G{alpha}oQ205L or GRIN1{Delta}(717-827), which lacks G{alpha}o binding region, promoted microspike formation in Swiss3T3 cells or neurite extention in Neuro2a cells. The dominant-negative mutant of Cdc42 blocked these morphological changes. Co-expression of GRIN1 and G{alpha}oQ205L stimulated formation of GTP-bound Cdc42 in Swiss3T3 cells. These results suggest that the binding of activated G{alpha}o to GRIN1 induces activation of Cdc42, which leads to morphological changes in neuronal cells.


Key words: Gi family, G protein regulation, Cdc42, rho, rac, other small G proteins


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
K. C. Slep, M. A. Kercher, T. Wieland, C.-K. Chen, M. I. Simon, and P. B. Sigler
Molecular architecture of G{alpha}o and the structural basis for RGS16-mediated deactivation
PNAS, April 29, 2008; 105(17): 6243 - 6248.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
Y. M.-S. Tay, W.-L. Tam, Y.-S. Ang, P. M. Gaughwin, H. Yang, W. Wang, R. Liu, J. George, H.-H. Ng, R. J. Perera, et al.
MicroRNA-134 Modulates the Differentiation of Mouse Embryonic Stem Cells, Where It Causes Post-Transcriptional Attenuation of Nanog and LRH1
Stem Cells, January 1, 2008; 26(1): 17 - 29.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics